細胞計數市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、應用、最終用途、地區和競爭格局分類，2021-2031年）

全球細胞計數市場預計將從 2025 年的 103.6 億美元成長到 2031 年的 163.9 億美元，複合年成長率為 7.95%。

此領域透過對生物樣本中的細胞進行定量分析，輔助醫學診斷、生物過程控制和藥物研發。推動市場發展的關鍵因素是全球慢性病發病率的上升以及生物製藥研發的成長，這兩者都需要嚴謹的細胞學分析。美國癌症協會的數據凸顯了這一臨床需求，該協會預測，到2025年，美國將新增2,041,910例癌症病例，這強調了精準細胞評估工具對於輔助準確診斷和治療方案製定的迫切需求。

儘管自動化設備具有良好的成長前景，但其高昂的實施和維修成本構成了市場推廣的一大障礙。現代流式細胞儀和數位計數器所需的大量資本投入，使得預算有限的學術機構和小規模實驗室難以採用這些設備。因此，這些經濟障礙迫使資源有限的機構依賴人工計數方法，阻礙了自動化技術在對成本敏感的區域市場的廣泛應用。

市場促進因素

生物技術和生物製藥研發的快速成長正成為市場的主要催化劑，催生了對先進測量設備的需求，以支持製程開發和藥物發現。隨著各機構加強對新型生物製藥的研發力度，對細胞濃度和活力進行精確分析的需求至關重要，以確保符合監管要求和實驗可重複性。研發投入的成長趨勢十分顯著。根據歐洲製藥工業協會聯合會 (EFPIA) 於 2024 年 6 月發布的《製藥業數據概覽》，2023 年歐洲製藥業的研發支出將達到 500 億歐元。這項巨額投資正推動自動化計數系統的採購，以應對臨床和臨床前試驗中日益增多的細胞分析需求。

同時，再生醫學和細胞療法日益成長的需求正在從根本上改變市場格局。嚴格的品管通訊協定對於包括CAR-T療法在內的細胞治療藥物的生產至關重要，而精確的細胞計數對於患者用藥劑量和產品療效評估至關重要。該領域的商業規模在大型生產合約中可見一斑。例如，三星生物製劑在2024年7月的新聞稿中宣布，已與一家美國製藥公司簽訂了一份價值10.6億美元的契約，用於擴大原料藥（API）的生產能力。此外，對該治療領域的投資依然強勁，推動了高通量計數解決方案的應用。根據再生醫學聯盟在2024年1月發布的「產業現況」報告，預計到2023年，全球細胞和基因治療領域將吸引117億美元的投資，這將確保對分析工具的持續需求。

市場挑戰

引入自動化細胞計數器需要大量的資金投入，這成為市場擴張的主要障礙。高階流式細胞儀和數位影像分析儀的購置成本高昂，對於採購預算有限的學術研究機構和中小型受託研究機構（CRO）而言，難以負擔。除了初始購置成本外，持續的營運成本，例如維護合約和專用試劑，也進一步抑制了對成本敏感的細分市場的潛在採購。因此，這些資金限制迫使許多資源有限的機構依賴人工計數技術，從而限制了自動化解決方案的潛在市場規模，並阻礙了收入成長。

科研經費停滯不前進一步加劇了這項經濟負擔，直接影響了科學界購置設備的能力。據美國實驗生物學會聯合會（FASEB）稱，美國國立衛生研究院（NIH）2024會計年度的聯邦預算約為471億美元，這一成長幅度不大，遠未跟上生物醫學領域的通貨膨脹速度。資金成長乏力限制了研究機構對資本密集技術的投資能力，並直接阻礙了現代細胞計數系統的廣泛應用。

市場趨勢

人工智慧 (AI) 和機器學習演算法的融合從根本上重新定義了細胞計數技術，實現了對複雜細胞形態的快速、無標記分析。這些先進的計算工具使研究人員能夠克服傳統染色技術的局限性，並在不損害細胞活性的前提下，即時精確地表徵細胞狀態。這種技術變革正日益被應用於高價值的治療工作流程中，在這些流程中，維持細胞完整性至關重要。例如，2025 年 9 月發布的題為「Deepcell 和 InGel Therapeutics 宣佈建立策略合作夥伴關係」的新聞稿指出，Deepcell 已與 InGel Therapeutics 合作，利用 InGel Therapeutics 的 AI 驅動的 REM-I 平台對視網膜細胞進行高維、無標定分析，以加速新型眼科治療方法的研發。

同時，隨著產業向更貼近生理實際的疾病模型轉型，針對類器官和3D細胞培養的專用計數解決方案的開發也日益加速。與單層培養不同， 3D模型需要高度標準化的分析通訊協定，以確保毒性測試和藥物篩檢應用中的可重複性。聯邦政府為推動類器官生產的產業化提供了重要支持。例如，美國國立衛生研究院（NIH）於2025年9月授予了一份總額達8700萬美元的契約，旨在促進「標準化類器官建模（SOM）中心」的建立，以開發擴充性且可重複的基於類器官的藥物發現和研究工作流程。相關消息已在題為「標準化類器官建模中心減少對動物模型的依賴」的新聞稿中公佈。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球細胞計數市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品分類（儀器（光強度、流式細胞儀、血球計數器、自動細胞計數器、顯微鏡等）、耗材及配件（試劑、微孔盤等））
  • 依應用領域（全血球計數（自動化、手動）、幹細胞研究、細胞療法、生物生物製程、毒理學、其他）
  • 按最終用戶分類（醫院和診斷機構、實驗室、研究機構和學術機構、製藥和生物技術公司、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美細胞數市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章 歐洲細胞計數市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區細胞計數市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲細胞計數市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美細胞計數市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球細胞計數市場：SWOT分析

第14章 波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc
• Merck KGaA
• Agilent Technologies, Inc.
• PerkinElmer Health Sciences Inc
• Becton Dickinson & Co
• Danaher Corp
• Bio-Rad Laboratories Inc
• BioTek Instruments Inc
• GE Healthcare Inc
• deNovis Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cell Counting Market is projected to increase from a valuation of USD 10.36 Billion in 2025 to USD 16.39 Billion by 2031, expanding at a CAGR of 7.95%. This sector involves quantifying cells in biological samples to facilitate medical diagnostics, bioprocess control, and pharmaceutical research. The market is primarily propelled by the rising global burden of chronic diseases and the growth of biopharmaceutical research and development, both of which require strict cytological analysis. This clinical need is highlighted by data from the American Cancer Society, which estimates that 2,041,910 new cancer cases will occur in the United States in 2025, underscoring the urgent necessity for precise cellular evaluation tools to support accurate diagnosis and treatment planning.

Despite these favorable growth prospects, the market encounters a major obstacle due to the high acquisition and maintenance costs linked to automated instrumentation. The significant capital investment needed for modern flow cytometers and digital counters limits their availability for academic institutions and smaller laboratories with restricted budgets. Consequently, these financial barriers often force resource-constrained facilities to continue relying on manual counting methods, which hinders the widespread adoption of automated technologies in cost-sensitive regional markets.

Market Driver

The rapid growth of biotechnology and biopharmaceutical research and development acts as a major catalyst for the market, creating a need for advanced instrumentation to support process development and drug discovery. As organizations increase their efforts to create novel biologics, the demand for accurate analysis of cell concentration and viability becomes essential to guarantee regulatory compliance and experimental reproducibility. This rising trend in development spending is significant; the European Federation of Pharmaceutical Industries and Associations reported in "The Pharmaceutical Industry in Figures" in June 2024 that the pharmaceutical industry's R&D expenditure in Europe hit €50,000 million in 2023. Such substantial financial commitment drives the purchase of automated counting systems to manage the growing volume of cell-based assays needed during clinical and preclinical phases.

Simultaneously, the increasing demand for regenerative medicine and cell-based therapies is fundamentally transforming the market landscape. Producing CAR-T and other cellular therapeutics necessitates strict quality control protocols, where precise cell enumeration is vital for establishing patient dosing and assessing product potency. The commercial scale of this sector is evident in major manufacturing deals; for example, Samsung Biologics announced in a July 2024 press release that it secured a $1.06 billion contract with a U.S. pharmaceutical company to enhance drug substance manufacturing capabilities. Moreover, investment in this therapeutic area remains strong, fueling the adoption of high-throughput counting solutions; according to the Alliance for Regenerative Medicine's January 2024 "State of the Industry" presentation, the global cell and gene therapy sector drew $11.7 billion in investment capital throughout 2023, ensuring continued demand for analytical tools.

Market Challenge

The substantial capital expenditure required for automated cell counting instrumentation represents a primary hurdle to market expansion. High-end flow cytometers and digital image-based analyzers come with steep acquisition costs, making them financially out of reach for academic laboratories and smaller contract research organizations with limited procurement budgets. Beyond the initial purchase price, significant ongoing operational costs, such as maintenance contracts and specialized reagents, further discourage potential buyers in cost-sensitive segments. As a result, these financial limitations force many resource-constrained facilities to depend on manual counting techniques, thereby limiting the total addressable market for automated solutions and retarding revenue growth.

This economic strain is further aggravated by stagnant research funding, which directly dictates equipment purchasing power within the scientific community. According to the Federation of American Societies for Experimental Biology, the 2024 federal budget for the National Institutes of Health was finalized at approximately $47.1 billion, a minor increase that failed to keep up with biomedical inflation. This lack of robust funding growth restricts the ability of research institutions to invest in capital-intensive technologies, directly impeding the broader integration of modern cell counting systems.

Market Trends

The incorporation of artificial intelligence and machine learning algorithms is fundamentally redefining cell counting by facilitating the high-speed, label-free analysis of complex cellular morphologies. These sophisticated computational tools allow researchers to circumvent the limitations of traditional staining techniques, offering precise, real-time characterization of cell states without harming viability. This technological shift is increasingly utilized in high-value therapeutic workflows where preserving cell integrity is essential. For example, in the "Deepcell and InGel Therapeutics Announce Strategic Partnership" press release from September 2025, Deepcell partnered with InGel Therapeutics to utilize its AI-driven REM-I platform for the high-dimensional, label-free analysis of retinal cells to expedite the development of new ocular therapies.

Concurrently, the creation of specialized counting solutions for organoids and 3D cell cultures is gaining momentum as the industry shifts toward physiologically relevant disease models. Unlike monolayer cultures, 3D models demand advanced standardization and analysis protocols to ensure reproducibility in toxicology and drug screening applications. This transition is supported by significant federal initiatives aimed at industrializing organoid production; for instance, the National Institutes of Health awarded contracts totaling $87 million in September 2025, as noted in the "Standardized Organoid Modeling Center to Reduce Reliance on Animal Modeling" press release, to launch the Standardized Organoid Modeling (SOM) Center, which is designed to develop scalable, reproducible workflows for organoid-based drug discovery and research.

Key Market Players

• Thermo Fisher Scientific Inc
• Merck KGaA
• Agilent Technologies, Inc.
• PerkinElmer Health Sciences Inc
• Becton Dickinson & Co
• Danaher Corp
• Bio-Rad Laboratories Inc
• BioTek Instruments Inc
• GE Healthcare Inc
• deNovis Inc

Report Scope

In this report, the Global Cell Counting Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Counting Market, By Product

• Instruments (Spectrophotometers, Flow Cytometers, Hemocytometers, Automated cell counters, Microscopes, Others)
• Consumables & Accessories (Reagents, Microplates, Others)

Cell Counting Market, By Application

• Complete Blood Count (Automated, Manual)
• Stem Cell Research
• Cell Based Therapeutics
• Bioprocessing
• Toxicology
• Others

Cell Counting Market, By End-use

• Hospitals &Diagnostic Laboratories
• Research & Academic Institutes
• Pharmaceutical & Biotechnology Companies
• Others

Cell Counting Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Counting Market.

Available Customizations:

Global Cell Counting Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Counting Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments (Spectrophotometers, Flow Cytometers, Hemocytometers, Automated cell counters, Microscopes, Others), Consumables & Accessories (Reagents, Microplates, Others))
  • 5.2.2. By Application (Complete Blood Count (Automated, Manual), Stem Cell Research, Cell Based Therapeutics, Bioprocessing, Toxicology, Others)
  • 5.2.3. By End-use (Hospitals &Diagnostic Laboratories, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cell Counting Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Counting Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada Cell Counting Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico Cell Counting Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-use

7. Europe Cell Counting Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Counting Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-use
  • 7.3.2. France Cell Counting Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom Cell Counting Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy Cell Counting Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain Cell Counting Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-use

8. Asia Pacific Cell Counting Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Counting Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-use
  • 8.3.2. India Cell Counting Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan Cell Counting Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea Cell Counting Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia Cell Counting Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-use

9. Middle East & Africa Cell Counting Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Counting Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE Cell Counting Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa Cell Counting Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-use

10. South America Cell Counting Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Counting Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia Cell Counting Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina Cell Counting Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Counting Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Agilent Technologies, Inc.
• 15.4. PerkinElmer Health Sciences Inc
• 15.5. Becton Dickinson & Co
• 15.6. Danaher Corp
• 15.7. Bio-Rad Laboratories Inc
• 15.8. BioTek Instruments Inc
• 15.9. GE Healthcare Inc
• 15.10. deNovis Inc

16. Strategic Recommendations

17. About Us & Disclaimer